The Cancer Target Discovery and Development (CTD²)

The purpose of the Cancer Target Discovery and Development (CTD²) Network is to learn how to use the compendia of cancer genomics information to systematically and efficiently develop new precision treatments. This is a critical time for National Cancer Institute (NCI) to aggressively pursue this direction, because comprehensive large-scale genomic projects, such as the Cancer Genome Characterization Initiative (CGCI), The Cancer Genome Atlas (TCGA), Therapeutically Applicable Research to Generate Effective Targets (TARGET), are producing an unprecedented amount of information about the molecular changes that underlie many different types of cancers. Consequently, this rapid pace of genome discovery has now overtaken our ability to turn that knowledge into viable therapies that target those specific molecular changes, leading to improved patient outcomes. CTD² accelerates the translation of genomic discoveries into new cancer treatments by assembling a network of different centers that contribute novel and complimentary scientific skills and approaches. It is managed by NCI’s Office of Cancer Genomics (OCG)

Funding Opportunity - new!

NCI has issued a new Request for Applications (RFA) for the CTD2 Network, RFA-CA-12-006 .

Click here for more information.

Projects/Centers

To view a list of the centers and projects that comprise the CTD² network, visit the CTD² program page on the OCG website. More detailed information is also accessible on the CTD²data matrix .

Data

The data generated by the centers is deposited on a web-based data portal that can be downloaded from this user-friendly data matrix. The CTD² Data Portal webpage contains an explanation of the data as well as links to the data release policy.

Tools

To facilitate the mining of the CTD² data in the future, the centers will soon provide bioinformatics tools.